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Abstract
Background—Injection drug use (IDU) in nonurban areas of the United States is a growing 
public health concern, but there has been no comprehensive assessment of existing research on 
injection-related HIV and hepatitis C (HCV) in nonurban communities. We conducted a 
systematic review to assess the current literature and identify knowledge gaps.
Methods—We systematically searched six databases for relevant articles published between 
January 1990 and June 2016 and screened, extracted, and analyzed the resulting data. Studies were 
included if they reported original findings from the nonurban U.S. related to 1) IDU and its role in 
HIV/HCV transmission, and/or 2) HIV/HCV services for people who inject drugs (PWID).
Results—Of 2,330 studies, 34 from 24 unique research projects in 17 states met inclusion 
criteria. Despite increasing HCV and high vulnerability to injection-related HIV outbreaks in 
nonurban areas, only three studies since 2010 recruited and tested PWID for HIV/HCV. Twelve 
reported on sharing injection equipment but used varying definitions of sharing, and only eight 
examined correlates of injection risk. Nine studies on syringe access suggest limited access 
through syringe exchange programs and pharmacies. Only two studies addressed HCV testing, 
none addressed HIV testing, and three examined behavioral or other interventions.
Conclusions—Despite growing concern regarding nonurban IDU there are few studies of 
HIV/HCV and related services for PWID, and the existing literature covers a very limited 
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geographical area. Current research provides minimal insights into any unique factors that 
influence injection risk and HIV/HCV service provision and utilization among nonurban PWID.
Keywords
Nonurban; Rural; HIV; HCV; IDU; PWID
1. Introduction
Injection drug use (IDU) is a risk factor for HIV, hepatitis C virus (HCV), and other blood-
borne infections. In the United States, six percent of new HIV diagnoses are attributed to 
IDU and another three percent to men who have sex with men (MSM) and inject drugs 
(Centers for Disease Control and Prevention, 2015a). While the overall number of newly 
diagnosed HIV cases among people who inject drugs (PWID) decreased between 2010 and 
2014 nationally, cases of acute hepatitis C almost tripled between 2010 and 2015 - an 
increase largely attributed to increases in IDU in nonurban areas (Centers for Disease 
Control and Prevention, 2015b) that are generally underserved by syringe access programs 
(Wejnert et al., 2016). Highly sensitive rapid tests are available to diagnose both HIV and 
HCV, yet the Centers for Disease Control and Prevention (CDC) estimates that 14% of all 
HIV-positive individuals and as many as half of those with chronic HCV are unaware of 
their infection (Hall et al., 2015; National Academies of Sciences, 2016). Early diagnosis of 
these infections is critical, as there are effective antiviral medications available that manage 
and cure HIV and HCV, respectively, and prevent onward transmission.
The growth of illicit drug use in U.S. nonurban areas over the past two decades has been 
covered extensively by the popular press but addressed in only a few peer-reviewed studies. 
These studies detail increases in methamphetamine use in nonurban areas in the early 2000s 
(Gruenewald et al., 2010; Gruenewald et al., 2013) and more recent increases in illicit 
prescription opioid and heroin use (Cicero et al., 2014; Meiman et al., 2015; Paulozzi and 
Xi, 2008; Rossen et al., 2013), but do not focus on IDU specifically. An HIV outbreak in 
Indiana received national attention as the first outbreak of its kind in a rural community, 
underscoring the importance of addressing IDU in nonurban areas. Between November 2014 
and November 2015, more than 180 individuals in Scott County, Indiana (population 
~23,000), tested positive for HIV, with most (88%) reporting injection of oxymorphone, a 
prescription opioid, within the past 12 months (Peters et al., 2016). CDC subsequently 
conducted a nationwide vulnerability assessment to identify counties at high risk of rapid 
HIV spread and new or continuing high rates of HCV infection among PWID (Van Handel 
et al., 2016); the 220 counties identified as most vulnerable were “overwhelmingly rural” 
(pg. 328). CDC also documented an almost four-fold increase in acute HCV infections 
among persons aged ≤30 years in Kentucky, Tennessee, Virginia, and West Virginia from 
2006–2012, noting that IDU was the most commonly reported risk factor and increases were 
substantially higher in nonurban than urban areas (Zibbell et al., 2015). All of these findings 
point to a pressing need for research on nonurban IDU, its health impacts, and effective 
public health responses.
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Although there is a wealth of peer-reviewed literature on IDU and HIV/HCV, the vast 
majority of studies have been conducted in urban areas, and it is unlikely that their findings 
are broadly generalizable to nonurban areas. Drug-related harms like HIV and HCV are the 
product of “risk environments” shaped by systemic and social contexts that vary across 
communities (Rhodes, 2002). For example, drug type and availability differ across 
geographic regions, resulting in different injection practices and HIV/HCV risk profiles 
(e.g., powder heroin vs. black tar heroin) (Ciccarone, 2009). The geospatial availability of 
harm reduction and other health services and access to transportation to reach these services 
are very different in urban and nonurban areas (Des Jarlais et al., 2015). Social norms and 
values differ across communities, contributing to variations in the stigma and discrimination 
that PWID encounter and its impacts on their decisions to seek care as well as their overall 
mental and physical health (Ahern et al., 2007; Young et al., 2005). Differences in social 
norms and values can also result in variation in the implementation of laws and policies that 
govern syringe possession, syringe access, and health services access (Burris et al., 2004; 
Chiarello, 2016; Pollini, 2017; Strathdee et al., 2015; Taussig et al., 2002). The result is that 
efforts to understand and address HIV/HCV among PWID should be “locally produced,” 
taking into consideration the specific factors that influence transmission in different 
communities (Rhodes, 2002).
To date, there has been no coordinated effort to summarize or synthesize the existing 
research on IDU and HIV/HCV in nonurban areas. Communities across the country are in 
need of research-based guidance on both the extent of the problem and effective strategies 
for HIV/HCV prevention, testing, and care in nonurban settings. In addition, research 
entities would benefit from insights regarding gaps in knowledge that remain to be filled by 
methodologically sound epidemiological and health services research studies. To address 
these needs, we undertook a systematic review of research on IDU and HIV/HCV in 
nonurban areas of the U.S., guided by three specific aims:
• Describe the existing literature on IDU and its role in HIV/HCV transmission in 
U.S. nonurban areas
• Characterize what is known about HIV/HCV-related services for PWID in U.S. 
nonurban areas
• Identify priority areas for research to fill current knowledge gaps regarding IDU, 
HIV/HCV transmission, and HIV/HCV-related services in U.S. nonurban areas
2. Material and Methods
Our systematic review was guided by the Preferred Reporting Items for Systematic reviews 
and Meta-Analyses (PRISMA) (Moher et al., 2009). The PRISMA checklist is included in 
the supplementary material for this article.1
1Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi: …
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We developed a detailed protocol and search-strategy in collaboration with two librarians, 
including one who specializes in systematic reviews, and registered our protocol with the 
International Prospective Register of Systematic Reviews (www.crd.york.ac.uk/prospero; 
CRD42016035780). We ran searches in six research databases (PubMed, CINAHL, 
PsycINFO, SCOPUS, CENTRAL, and CDSR) for articles published between January 1, 
1990, and the search date of June 13, 2016. Searches used database-specific medical subject 
headings (e.g., MeSH), as well as Boolean operators, truncation, and wildcards in addition to 
keywords, when possible (Table 1). We imported database search results into EndNote, 
recorded results on an Excel spreadsheet, and deleted duplicates.
2.2. Inclusion and Exclusion Criteria
We included articles reporting original findings related to 1) IDU and its role in HIV and/or 
HCV transmission in nonurban areas of the U.S., and/or 2) availability of, access to, and/or 
effectiveness of HIV- and/or HCV-related services for PWID in nonurban areas of the U.S. 
To be eligible, articles had to report results specific to nonurban areas or populations. 
Nonurban eligibility was determined by study authors’ definition, when available; 
specifically, articles were eligible if the authors described their sample as “rural” or 
“nonurban.” For articles with unclear descriptors (e.g., “suburban,” “semi-urban,” etc.), 
multiple descriptors (e.g., “urban” and “rural”), or no explicit indication of rural/urban 
context, we used the Census Bureau’s urban-rural classification for cities and towns (e.g., if 
listed as an urban area or urban cluster, the city or town was considered urban) (United 
States Census Bureau, 2010) or the USDA Economic Research Service rural-urban 
continuum codes for counties (i.e., counties with a rural-urban continuum code of 4 to 9 
were considered nonurban) (United States Department of Agriculture Economic Research 
Service, 2013). Studies that included both urban and nonurban areas were included if they 
reported relevant findings specific to nonurban areas.
Only original peer-reviewed manuscripts were included; we excluded letters, editorials, and 
news articles. Additional exclusion criteria were dissertations, non-English language 
publications, non-human study subjects, research conducted outside of the U.S. (all 50 states 
and the District of Columbia were eligible for inclusion), research conducted solely in urban 
areas or with urban populations, research conducted in prisons (due to challenges of 
establishing rural/urban status of prison inmates), and articles published before 1990 (to 
exclude less relevant research from the early years of the HIV/AIDS epidemic).
2.3. Study Selection
Two reviewers independently applied inclusion and exclusion criteria to each article. 
Incongruent results were discussed by the two reviewers until they reached consensus, with 
the option of having any unresolved discrepancies decided by a third reviewer. We calculated 
inter-rater reliability using kappa statistics, as per recommendations made in the Cochrane 
Handbook for Systematic Reviews of Interventions (Higgins and Green, 2011). After study 
selection, we validated our search results by conducting cited and citing reference searches.
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2.4. Data Extraction and Analysis
After identifying the final set of eligible manuscripts, we recorded additional information 
about each study. This included basic study characteristics (publication date, year(s) of data 
collection, specific location/geographical area studied, and population studied); study aims 
and methods (research aims, recruitment methods, and primary outcomes and measures); 
and the study’s primary results, conclusions, and implications in relation to our research 
questions (including which of our research aims were addressed by the study). Two 
independent reviewers also made notes about the methodological strengths and weaknesses 
of each study. We then grouped all results by study aim and examined and analyzed the main 
findings, identifying primary themes, implications, and gaps in the research.
3. Results
3.1. Search Results
Our initial searches retrieved 3,563 references. We organized and de-duplicated these 
references, resulting in 2,330 unique references that we considered for inclusion. Based on 
abstract review we identified 361 articles that were eligible for full-text review. Of these, 230 
articles were ineligible based on our exclusion criteria, and 97 did not meet our indicators of 
relevance. The remaining 34 studies were eligible for inclusion in our review.
3.2. Description of Included Studies
Of the 34 studies included, 26 reported results related to the role of IDU in HIV/HCV 
transmission in nonurban areas and 13 reported results related to HIV/HCV-related services 
for PWID in nonurban areas. Publication dates ranged from 1990 to 2016; more than half 
(56%) were published after 2010, 26 percent were published between 2000 and 2010, and 18 
percent were published prior to 2000.
The 34 included studies drew from 24 unique research projects. Three used national samples 
and the remaining 31 reported data from 17 states. The studies tended to concentrate in a 
few geographical areas, with half (17 of 34) collecting data in one of only three states: 
Kentucky, Connecticut, and Florida. Fourteen studies were conducted in Kentucky; of these, 
10 (29% of all included studies) were conducted solely in Kentucky, while an additional four 
used multistate (but not national) samples including Kentucky.
3.3. Role of IDU in HIV/HCV Transmission in Nonurban Areas
A majority of studies (74%, n=25) reported results addressing the role of IDU in HIV/HCV 
transmission in nonurban areas. These articles typically addressed HIV/HCV prevalence 
and/or correlates of infection among PWID.
3.3.1. HIV/HCV prevalence—Sixteen studies reported on HIV/HCV prevalence among 
PWID in nonurban areas. Three used secondary data to examine national or regional trends; 
five involved HIV/HCV testing with PWID as part of a larger group, providing IDU-specific 
estimates; five recruited PWID specifically and tested them for HIV and/or HCV; and four 
collected data on HIV and/or HCV prevalence via self-report methods.
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3.3.1.1. Secondary data used to examine national or regional trends: These three studies 
indicate that HIV diagnoses among PWID have decreased in both urban and nonurban areas 
in recent years, while HCV diagnoses have been increasing – a change that has been most 
dramatic in nonurban areas. Using data from the CDC’s National Notifiable Disease 
Surveillance System, one study found that HIV diagnoses decreased significantly between 
2008–2014 in both urban and nonurban areas, though these decreases were smaller for 
nonurban whites than for other groups (Wejnert et al., 2016). Two others also used CDC data 
to examine trends in acute HCV infections. Zibbell et al. (2015) found that between 2006 
and 2012, 74.8% of HCV cases among persons aged ≤30 years in nonurban areas of 
Kentucky, Tennessee, Virginia, and West Virginia were related to IDU, and HCV incidence 
was four times greater in nonurban areas than in urban areas during this period. Van Handel 
et al. (2016) examined nationwide data at the county level to identify counties at highest risk 
of an HIV outbreak, using acute HCV infections as a proxy for needle sharing. Although 
they did not report detailed results related to urbanicity, the authors concluded that the 
counties most at risk of an HIV outbreak were “overwhelmingly rural” (pg. 328).
3.3.1.2. Estimating IDU-specific burden: Five studies examined HIV and/or HCV burden 
attributed to IDU within a larger group of study subjects. Two of these recruited individuals 
living with HIV from clinical settings. Cohn et al. (1994) surveyed 325 HIV-positive patients 
seen at UNC Hospitals in North Carolina; 10% (n=34) reported a history of IDU. Grace et 
al. (2000) recruited 119 patients who were treated at HIV specialty clinics in rural Vermont. 
They reported that IDU and IDU/MSM transmission risk accounted for 23% of HIV cases, 
noting that a disproportionate number of women were infected via IDU.
The remaining three studies recruited or used data from state or local health departments. A 
study from rural Appalachian Kentucky recruited individuals who received HCV/hepatitis B 
virus (HBV) testing at four health departments (Christian et al., 2010). Eight of the 12 
individuals who had a positive HCV antibody test had a history of IDU (a 57% HCV-
positivity rate among PWID). Conrad et al. (2015) examined data from the Indiana State 
Department of Health after the 2015 HIV outbreak in rural Indiana; 80% of those infected 
were PWID. Sheehan et al. (2015) used HIV surveillance data from the Florida Department 
of Health to examine trends among HIV-positive Latinos between 2000 and 2008. Ten 
percent of their sample (n=1126) were reported as having a history of IDU, and those with a 
history of IDU were more likely to live in a rural area.
3.3.1.3. PWID recruited and tested: Of the five studies in this category, two were 
conducted in the 1990s with small sample sizes. Wykoff et al. (1991) recruited and tested 
injection partners of people who tested positive for HIV in a rural South Carolina district, 
documenting 26.7% prevalence. McCoy et al. (1996) recruited 10 PWID in Belle Glade, 
Florida, and found that four tested positive for HIV. More recent studies had much larger 
sample sizes. Havens et al. (2013) used respondent-driven sampling (RDS) to recruit and test 
392 PWID between 2008 and 2010 in Appalachian Kentucky, finding an HCV prevalence of 
54.8% and no positive HIV results. Akselrod et al. (2014) also used RDS to recruit and test 
446 PWID in suburban Connecticut between 2008 and 2011, finding an HCV prevalence of 
40.1% and HIV prevalence of 3.1%. Zibbell et al. (2014) used modified snowball sampling 
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to recruit and test 123 PWID in rural Courtland County, New York in 2012 and found an 
HCV prevalence of 34%.
3.3.1.4. Self-report: Four studies used self-report methods to quantify HIV or HCV 
prevalence. Two of these were conducted by the same research team in rural Appalachian 
Kentucky in the early 2000s. In one, the researchers recruited 800 felony probationers 
between 2001 and 2004; of the 179 individuals with a lifetime history of IDU, 12.8% 
reported HCV-positive status and none reported HIV infection (Havens et al., 2011). In the 
other, Havens et al. (2007) recruited 184 opioid users, including 19 who were currently 
injecting drugs, from 2004 to 2005. They found that 14.8% of current PWID self-reported 
HCV-positive status. In their study of PWID in New York, Zibbell et al. (2014) found no 
self-reported cases of HIV. In rural Kentucky, Staton-Tindall et al. (2015b) facilitated focus 
groups with 22 women from three rural Kentucky jails who reported drug use; the authors 
reported that most women perceived IDU was extremely common in their communities and 
that HCV was widespread.
3.3.2. HIV/HCV risk behaviors—Fourteen studies reported on injection practices that 
facilitate HIV/HCV transmission. These include sharing syringes, other injection equipment 
(e.g., cotton, cookers), and water used for dissolving drugs or rinsing injection equipment. 
Studies varied in the measures used to assess injection-related behaviors; for example, some 
used measures of “syringe sharing” while others considered “receptive” and “distributive” 
sharing separately. Similarly, some reported broadly on injection “works” or “other injection 
paraphernalia” while others reported separately estimates for sharing cotton, cookers, and/or 
water. Timeframes for assessing injection risk behaviors also varied, encompassing the 
periods past 30 days, past 6 months, past year, and lifetime. Three studies went beyond 
measuring the prevalence of these behaviors to investigate factors associated with engaging 
in them, while an additional four undertook biological testing for HIV/HCV and identified 
statistically significant correlates of infection. Ten studies used community-based samples 
and four derived samples from criminal justice populations.
3.3.2.1. Syringe sharing: Twelve studies reported measures of syringe sharing. Three from 
a single cohort of PWID in southwestern Connecticut reported syringe-mediated sharing 
(not defined) at 13% (Akselrod et al., 2014), receptive sharing at 21.9% (Grau et al., 2016), 
and “syringe sharing” at 20.5% (Heimer et al., 2014). A community-based sample in 
Appalachian Kentucky documented receptive and distributive syringe sharing at 10.5% and 
26.3%, respectively (Havens et al., 2007), while a later study documented prevalence of 
16.7% for receptive and distributive sharing combined (Young et al., 2013b). A third study 
from this region estimated receptive syringe sharing at 30.2% and 15.2% for HCV-positive 
and HCV-negative participants, respectively (Havens et al., 2013). The highest community-
based estimate of syringe sharing came from central New York State, where Zibbell et al. 
(2014) found that 44.4% of young adult PWID reported sharing needles in the past 12 
months. A final community-based, multi-site study reported that 12.9% of participants in 
“low population density communities” reported using “unclean works” in the past 30 days, 
which we interpreted as including syringes (Leukefeld et al., 2001).
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The remaining four studies, conducted among criminal justice populations, documented 
higher syringe sharing prevalence than the aforementioned community-based samples. 
These include two studies of probationers in Kentucky; the first documented lifetime 
receptive and distributive syringe sharing at 34.5% and 97.1%, respectively (Havens et al., 
2011). The second found that distributive syringe sharing ranged from 32.6% to 54% 
depending on recipient type (e.g., other users, sexual partners, or friends) and that 75.3% 
“often” sold or gave away their needles or works without cleaning (Oser et al., 2006). The 
third study, among women currently in jail in Kentucky, reported that 70.3% shared needles 
in the past year (Staton-Tindall et al., 2015a). The fourth, from Indiana, reported that 6% of 
jail inmates and 3% of jail staff cited needle use as a mode of HIV transmission in jails 
(Kane and Dotson, 1997).
3.3.2.2. Sharing other injection equipment: Eight studies addressed injection equipment 
other than syringes. Two, from the same Connecticut-based study, reported slightly differing 
prevalence for sharing cookers (18.8% and 17.8%), rinse water (31.2%, 30.0%), and drug 
mixing water (33.8%, 34.8%) in the past 30 days (Grau et al., 2016; Heimer et al., 2014). 
Other studies grouped non-syringe injection equipment together; these included two 
community-based Kentucky studies, with one reporting that 42.1% of PWID shared cotton/
cookers/rinse water (Havens et al., 2007) and the other that 41.9% of HCV-positive and 
26.0% of HCV-negative PWID, respectively, shared cookers/cotton/rinse water in the past 6 
months (Havens et al., 2013). In New York, Zibbell et al. (2014) reported that 68.3% of 
young adult PWID shared cotton/cookers/water in the past year. Among female jail inmates 
in Kentucky, 96.6% reported sharing cookers/cotton/rinse water in past year (Staton-Tindall 
et al., 2015a). In a sample of Kentucky probationers, 44% had shared injection equipment 
like cotton and cookers in their lifetime (Havens et al., 2011); a second study of Kentucky 
probationers by Oser et al. (2006) combined reporting of sharing “works” with sharing 
needles, as noted above.
3.3.2.3. Correlates of risky injection and HIV/HCV infection: Five studies tested for HIV 
and/or HCV and examined correlates of infection. Among young adult PWID in central New 
York, sharing any injection equipment (excluding syringes) and injecting prescription 
opiates were independently and positively associated with HCV infection, while female 
gender was inversely associated (Zibbell et al., 2014). In Kentucky, Havens et al. (2013) 
identified an independent association between syringe sharing and HCV but not sharing 
cotton/cookers/water. White race, prescription opioid injection, cocaine injection, testing 
positive for herpes simplex virus 2, having injected for at least one year, and “eigenvector 
centrality” (a social network measure) were also independently positively associated with 
HCV, while having a PTSD diagnosis was inversely associated with infection (Havens et al., 
2013). Young et al. (2013a) found that recent IDU was associated with HCV infection. A 
third study of one urban and two nonurban Florida communities showed a positive 
association between IDU and HIV seropositivity only in the urban site in univariate analysis 
(McCoy et al., 1999). In Connecticut, Akselrod et al. (2014) undertook biological testing for 
HIV/HCV/HBV and conducted multivariate analysis to identify independent associations 
with testing positive for one or more viruses but did not appear to examine sharing of 
syringes and/or other injection equipment as a covariate in the analysis.
Paquette and Pollini Page 8













Three additional studies looked at factors associated with risky injection behaviors rather 
than HIV/HCV. Two of these studies, from the Connecticut cohort, looked at factors 
associated with a composite injection-associated risk behavior outcome variable based on 
participants’ reports of engaging in up to six listed risk behaviors in the last 30 days (i.e., 
receptive sharing, “syringe mediated sharing,” sharing drug in liquid form, sharing cookers, 
sharing drug-mixing water, sharing rinse water). Grau et al. (2016) looked at factors 
associated with reporting at least one of these behaviors and identified White race, having at 
least a high school degree, and having ≥6 injection partners in past 6 months as positively 
associated with injection risk behavior(s). Heimer et al. (2014) used this measure as a 6-item 
continuous outcome variable and found that older age, CES-D depression score normal or 
mild, injecting in one’s own residence, and higher social support scores were negatively 
associated with higher risk scores, while larger injection network size and higher hepatitis 
knowledge score were positively associated with higher scores. The third study, among 
Kentucky probationers, reported that risky injection practices (defined as engaging in 
receptive syringe sharing or sharing other injection equipment) were positively associated 
with being male, lifetime cocaine injection, and lifetime opioid injection, and negatively 
associated with older age and being African American, after controlling for potential 
confounders (Havens et al., 2011).
3.4. HIV/HCV-Related Services for PWID in Nonurban Areas
Thirty-eight percent of included studies (n=13) examined HIV/HCV-related services for 
PWID in nonurban areas. These articles examined syringe access, HIV/HCV testing, and 
other interventions including a risk reduction intervention and a partner notification program 
for individuals who tested positive for HIV.
3.4.1. Syringe access—Nine studies examined some aspect of syringe access for PWID 
in nonurban areas of the United States. These studies demonstrate that nonurban areas lack 
syringe exchange programs (SEPs) and thus PWID in these areas often rely on 
nonprescription syringe sales at pharmacies or on secondary sources such as friends, drug 
dealers, and other PWID. Many states permit nonprescription syringe sales at the 
pharmacists’ discretion; the included studies also highlight how this provision results in 
inconsistent access to sterile syringes via pharmacies in nonurban areas.
3.4.1.1. Limited SEPs and reliance on pharmacies and secondary sources: Only one 
study examined access to sterile syringes through SEPs in nonurban areas. In a survey of 
SEPs across the United States, Des Jarlais et al. (2015) found that only 20% of SEPs were 
located in rural areas, and 9% in suburban areas. The authors noted that in addition to having 
fewer SEPs, nonurban areas typically had smaller SEPs which served fewer clients and had 
less funding. The lack of access to free syringes in nonurban areas may result in a reliance 
on pharmacies and secondary sources for sterile syringes. Akselrod et al. (2014) found that 
in suburban Connecticut, where at the time of the study there was only one SEP in each 
county studied, 74.2% of PWID usually purchased syringes from a pharmacy, while only 
3.3% obtained syringes from a SEP in the past 30 days. In Kentucky, Havens et al. (2011) 
found that only a third of felony probationers with a lifetime history of IDU reported 
obtaining syringes from legal sources. In a later study, Havens et al. (2013) found that 
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among participants with a lifetime history of IDU, fewer than 4% regularly bought syringes 
from pharmacies, while most got them from family, friends, or dealers. Relatedly, in 
qualitative interviews with methamphetamine users in Tennessee, MacMaster et al. (2008) 
reported that their participants identified syringe access (including nonprescription 
pharmacy syringe sales) as a service that was lacking in their community.
3.4.1.2. Inconsistent pharmacy access: The reliance on pharmacies for sterile syringes can 
be problematic because state laws generally either allow nonprescription syringe sales at the 
individual pharmacist’s discretion or more proactively promote nonprescription syringe sales 
but only with voluntary pharmacy participation. Reich et al. (2002) found that in Missouri, 
Kentucky, and Colorado pharmacies were the most common source of syringes for PWID, 
but PWID in urban areas had an easier time accessing syringes at pharmacies than those in 
rural areas. Compton et al. (2004) found similar results in Kentucky, where rates of 
successful syringe purchases were higher in urban regions than in rural regions. In that 
study, however, they found an opposite trend in Colorado, Connecticut, and Missouri (i.e., 
rural areas had higher rates of successful syringe purchase than urban areas in those states). 
Stopka et al. (2002) found that in urban and suburban areas of Connecticut, syringe purchase 
attempts overall were significantly more successful in suburban vs. urban pharmacies but 
purchase attempts at chain pharmacies were more successful in urban areas. Overall, these 
studies highlight inconsistent access to syringes at pharmacies: access appears to vary from 
state to state and across urban vs. nonurban areas within states and may also vary by 
pharmacy type.
3.4.2. HIV/HCV-related services—Five studies examined services for PWID related to 
HIV and/or HCV in nonurban areas. These studies highlight a lack of access to HIV and 
HCV testing in these areas, as well as an overall lack of effective risk reduction 
interventions.
3.4.2.1. Testing: Two studies examined the availability of HCV testing in nonurban areas, 
while none reported results related to the availability of HIV testing. Staton-Tindall et al. 
(2015b) reported that the women they interviewed in rural Kentucky jails believed services 
and testing for HCV were very limited, and the authors noted that the local Health 
Department did not offer HCV testing. Barocas et al. (2014) surveyed PWID who utilized an 
SEP in Southern Wisconsin in 2012. The researchers found that PWID who lived in rural 
areas were less likely to report recent HCV testing than those who lived in urban and 
suburban areas, and that participants who lived in urban areas were more likely to have been 
tested in the past year than those who lived in rural and suburban areas. In that study, lack of 
transportation was identified as a barrier to testing.
3.4.2.2. Risk reduction: Two studies examined programs or interventions which aimed to 
reduce HIV/HCV risk among PWID in nonurban areas. Knittel et al. (2010) studied clients 
who enrolled in an SEP at an HIV/AIDS resource center in Ypsilanti, MI between 2004 and 
2006 to examine the impact of SEP participation on risk behaviors. The researchers found 
that at six months after enrollment, clients were less likely to report giving someone else a 
used syringe than at enrollment; no other variables related to HIV risk reduction reached 
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significance. Warner and Leukefeld (2001) studied an HIV risk reduction intervention for 
PWID and people who used crack/cocaine in Kentucky. The researchers found that PWID in 
their “most” rural site actually increased injection risk behaviors after the intervention.
3.4.2.3. Other interventions: One additional study examined the acceptability of a partner 
notification intervention for sex and injection partners of individuals who tested positive for 
HIV in a rural South Carolina district between 1988 and 1989. Jones et al. (1990) reported 
that most respondents in all groups, including injection partners, were in favor of the partner 
notification program.
4. Discussion
Our review documented only a small number of studies examining IDU and HIV/HCV in 
non-urban areas of the U.S. between 1990 and 2016. This finding is at odds with the 
extensive media and policy focus on nonurban illicit drug use in the past two decades and 
indicates an urgent need for targeted, high quality public health research on HIV/HCV 
transmission, testing, and treatment among PWID in these underserved areas.
The national epidemiological assessments in our review indicate that HCV is rising in 
nonurban areas and that these areas are at disproportionately high risk of an HIV outbreak 
(Van Handel et al., 2016; Wejnert et al., 2016; Zibbell et al., 2015). We documented only 
five studies – just three since 2010 – that specifically recruited and tested nonurban PWID 
for HIV and/or HCV. The three recent studies used community-based recruitment methods 
to test a total of 961 PWID for HCV; prevalence ranged from 34 percent in New York 
(Zibbell et al., 2015) to 55 percent in Kentucky (Havens et al., 2013). Only two of the three 
studies also tested for HIV, with prevalence ranging from zero (Havens et al., 2013) to three 
percent (Akselrod et al., 2014). This constitutes a substantial gap in knowledge regarding 
HIV/HCV prevalence among nonurban PWID, providing insufficient data upon which to 
base broader estimates of HIV/HCV prevalence in U.S. nonurban areas. Well-designed 
prevalence studies in strategically selected community-based samples across the U.S. are 
critical to efforts to establish nationwide prevalence estimates and establish a broad strategy 
for targeting and implementing HIV/HCV prevention and treatment strategies for nonurban 
PWID.
The limited number of community-based studies also raises concerns regarding 
methodological limitations of the current literature regarding nonurban IDU and HIV/HCV. 
Specifically, our review documented an overreliance on convenience samples, primarily 
recruited from health care settings and often resulting in samples of less than 100 PWID. A 
growing number of studies document the marginalization of PWID from society in general 
(e.g., Capitanio and Herek, 1999) and health services in particular (e.g., Ding et al., 2005; 
Etesam et al., 2014; Luoma et al., 2007), raising concerns about the generalizability of 
existing findings. Further, some studies used problematic exposure and outcomes measures, 
with at least two relying on self-report of HIV and/or HCV status. Many of these limitations 
may have resulted from difficulties in recruiting community-based PWID in nonurban areas, 
where until recently there were few harm reduction programs in operation that could link 
researchers with eligible research participants. Limited funding for nonurban research on 
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these issues may also have played a role. As nonurban harm reduction programs expand, 
there should be additional opportunities for research using recruitment methods like RDS 
that extend recruitment beyond service PWID who access health services. With regard to 
funding, we note that the National Institute on Drug Abuse, in collaboration with several 
other federal agencies, is making targeted funding available to address opioid use in rural 
U.S. regions (RFA-DA-17-014). Nonetheless, the findings of this review highlight the need 
for rigorous recruitment and data collection methods in this area, including recruitments of 
sufficient size and statistical power to draw conclusions about appropriately measured 
outcomes of interest.
With regard to testing, we identified only two studies on HCV testing in nonurban areas, 
both conducted with convenience samples, and none addressing HIV testing. Notably, one of 
the two studies found lower HCV testing among nonurban participants. Biological testing is 
critical to national efforts to “seek, test, treat, and retain” (NIDA, 2013) those infected with 
HIV and identify HCV-infected individuals who may benefit from new highly effective 
antiviral therapies. Research characterizing the availability of HIV/HCV testing and barriers 
to testing among PWID in nonurban areas could make invaluable contributions to both 
HIV/HCV surveillance efforts and interventions to improve testing engagement and timely 
entry into care. Research on barriers to HIV/HCV treatment for those who test positive is 
especially needed, as our review failed to identify even one study examining HIV/HCV 
treatment engagement and retention among nonurban PWID.
We identified a comparatively large number of studies examining HIV/HCV risk factors 
among PWID, albeit from a very small number of states, in both community and 
institutional samples. Definitions of syringe sharing and the inclusion and/or categorization 
of other injection equipment varied across studies; promoting standardization in these 
measures would facilitate comparisons across nonurban PWID studies in geographically 
diverse areas of the U.S. and help prioritize interventions. Such standardization might 
include consistently measuring the frequency of both receptive and distributive syringe 
sharing and individually assessing the sharing of “other” injection equipment like cotton, 
cookers, and rinse water. That said, recent work by Heimer et al. (2017) indicates that it is 
the process of preparing drugs with used syringes, rather than the sharing of preparation 
paraphernalia itself, that contributes to HCV transmission. This finding should be 
incorporated into nonurban and urban surveys alike by including standardized questions on 
“booting” (pulling drug back into the syringe after injecting and then reinjecting), and using 
previously used syringes to add water for dissolving and/or apportioning drugs after mixing.
Notably absent from these studies was consideration of structural factors and their potential 
impact on PWID decisionmaking; more specifically, what does the “risk environment” look 
like in nonurban communities and how does it influence injection risk behaviors? The Des 
Jarlais et al. study (2015) documented a comparatively small number of SEPs in nonurban 
compared to urban areas and others documented participant reports of limited sterile syringe 
access (Havens et al., 2013; Havens et al., 2011; MacMaster et al., 2008; Staton-Tindall et 
al., 2015b). Understanding how limited syringe access and other structural factors (e.g., 
policing practices, stigma, transportation issues) influence injection-related HIV/HCV risk 
in nonurban areas, so that appropriate interventions can be implemented, should be a priority 
Paquette and Pollini Page 12













for research. Studies comparing the impact of structural- and individual-level factors that 
influence HIV/HCV risk behaviors and care seeking among PWID in nonurban and urban 
areas might also provide insights into whether and how research conducted in urban 
communities can be applied to nonurban communities and vice versa.
In addition to the small number of studies documented in our review, the lack of geographic 
breadth in these studies is an issue of significant concern. Only two states west of the 
Mississippi River were included; large portions of the southern U.S. and most of the 
Northeast were also excluded, as were states like Ohio and West Virginia that have been 
hard-hit by the current opioid epidemic. Our study should be viewed as a wake-up call 
regarding the lack of peer-reviewed research on nonurban drug-related HIV/HCV across the 
U.S.; such research is integral to inform efforts designed to prevent and address injection-
related HIV outbreaks and the continued spread of HCV in these underserved communities.
Our systematic review has limitations. To be included in our review, studies had to include a 
nonurban identifier (e.g., “rural,” “nonurban,” or “suburban”) or a variant of the word 
“region” somewhere in the searchable reference text, including title, abstract, and keywords. 
Studies that do not include such identifiers would have been missed by our searches, and 
thus our review likely did not identify all relevant studies. This limitation also has important 
public health implications, as relevant studies that were not found by our review will also not 
be easily identified by academic and community stakeholders seeking to learn from existing 
nonurban studies for research, practice, or policy-related purposes. Including a descriptor of 
the study setting in searchable reference text for would facilitate the dissemination and 
application of new information on IDU and HIV/HCV in nonurban areas.
5. Conclusions
Our systematic review documented only 34 U.S.-based studies of IDU and HIV/HCV in 
nonurban areas between 1990 and 2016, covering an extremely limited geographic area. 
These studies document increasing HCV and high HIV vulnerability but offer limited 
information on the factors that contribute to HIV/HCV risk among nonurban PWID. There is 
also extremely limited information about barriers to HIV/HCV testing and treatment among 
nonurban PWID. Future research should address these issues with rigorous methodological 
approaches and broader geographic reach, and clearly, indicate that findings refer to 
nonurban communities.
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• Injection drug use (IDU) in the nonurban U.S. is a growing public health 
concern.
• Studies document increasing HCV and high HIV vulnerability related to 
nonurban IDU.
• There is limited information on factors that contribute to nonurban HIV/HCV 
risk.
• Few studies examine HIV/HCV testing or treatment among nonurban 
injectors.
• There is an urgent need for research to inform IDU interventions in nonurban 
areas.
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Map of Studies included in systematic review Note: Excludes studies with national samples. 
Number of PWID in each study is geocoded in the main location of each study, including for 
studies with multistate samples.
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Table 1
Search terms and subject headings used
Word group 1 Word group 2 Word group 3
Search terms
suburb*, rural, exurb*, non-urban, nonurban, 
urban fringe, peri-urban, periurban, region*
syringe*, injecti* drug use, needle exchange, 
syringe exchange, needle sharing, syringe 
sharing, intravenous injecti*, intravenous drug 
us*, intravenous drug abus*, IDU, IVDA, PWID
HIV, HCV, hep* C, human 
immunodeficiency virus, AIDS, 
acquired immunodeficiency syndrome, 
acquired immune deficiency syndrome
MeSH Headings
Rural Health Services, Suburban Health 
Services, Rural Nursing, Suburban Population, 
Rural Population
Needle-Exchange Programs, Needle Sharing, 
Injections, Needles, Syringes, (Substance Abuse, 
Intravenous)
HIV Infections, Hepatitis C
PsycINFO Headings
Rural Environments, Suburban Environments Needle Sharing, Needle Exchange Programs, 
Intravenous Injections, Injections, Intravenous 
Drug Usage
HIV, HIV Testing, AIDS Prevention, 
AIDS, Hepatitis
CINAHL Headings
Rural Population, Rural Health Services, Rural 
Health Nursing, Rural Areas, Rural Health, 
Suburban Areas, Suburban Population, 
Suburban Health
Needles, Needle Sharing, Needle Exchange 
Programs, Syringes, (Injections, Intravenous), 
Injections, (Substance Abuse, Intravenous), 
Intravenous Drug Users, (Administration, 
Intravenous)
HIV-Infected Patients, HIV Infections, 
HIV Education, Hepatitis C, (Hepatitis 
C, Chronic)
Note: Search terms within groups combined with OR. Word groups combined with AND. Date restrictions were set for all searches from 
01/01/1990 to 12/31/2016. All searches were conducted on 06/13/2016; date restrictions were set to capture pre-publication results available in 
online databases.


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Drug Alcohol Depend. Author manuscript; available in PMC 2019 July 01.
